Chronic lymphocytic leukemia/small lymphocytic lymphoma
Therapeutic area
Hematology
Rare disease
No
- Definition
- An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Therapeutic area
- Hematology
- chronic lymphocytic leukemia/small lymphocytic lymphoma
- CLL/SLL
- chronic lymphocytic leukemia/small lymphocytic lymphoma
- chronic lymphocytic leukemia/small lymphocytic lymphoma (morphologic abnormality)
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0003864
- Parent condition
- MONDO:0004948
Related records
Broader conditions (29)
- Acute disease
- Acute leukemia
- Acute lymphoblastic leukemia
- B-cell chronic lymphocytic leukemia
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Chronic leukemia
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Indolent B-cell non-Hodgkin lymphoma
- Leukemia
- Leukocyte disorder
- Lymphoid hemopathy
Narrower conditions (2)
- Chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation
- Pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma
Trials (65)
- A Case Crossover Study of Intermittent Fasting in CLL/SLL
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
- A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
- A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
- A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Drugs in development (1)
- Acalabrutinib Phase 2